Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy

Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy

This pilot study (NCT03958097; https://www.clinicaltrials.gov/ct2/show/NCT03958097) was aimed to evaluate the efficacy and safety of PD-1 antibody combined autologous NK cells in the treatment of patients with stage IIIB/IIIC or IV non-small-cell lung cancer (NSCLC) who failed the first-line platinu...

Full description

Bibliographic Details
Main Authors: Lin Jia, Naifei Chen, Xiao Chen, Chao Niu, Ziling Liu, Kewei Ma, Nanya Wang, Lei Yang, Yuguang Zhao, Wei Song, Jin Lu, Chen Chen, Xiaofeng Cong, Xu Wang, Yinghui Xu, Guozhen Cui, Zengguang Liu, Rongrong Chen, Wei Li, Jiuwei Cui
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Immunology
Subjects:
non-small cell lung cancer
PD1 antibody
NK cells
immunotherapy
immune cell therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1074906/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1074906/full

Similar Items